Adsorbents for chronic diarrhoea in people with HIV/AIDS
A Cochrane review 1 included 1 study with a total of 91 subjects. The trial including patients from African French speaking countries assessed the use of an adsorbent (attapulgite) compared to a placebo for chronic diarrhoea in people with HIV/AIDS experiencing diarrhoea for at least 7 days. There was no evidence that attapulgite is superior to placebo in controlling diarrhoea by reducing stool frequency and normalising stool consistency on days 1 (RR 0.34 95% CI 0.01 to 8.15), 3 (RR 1.35 95% CI 0.51 to 3.62) and 5 (RR 1.74 95% CI 0.89 to 3.38). Five deaths were reported which was not classified according to the arms of the study. Studies assessing the use of antimotility agents were not found.
Comment: The quality of evidence is downgraded by study quality (several issues) and by imprecise results (few patients and wide confidence intervals).
1. Nwachukwu CE, Okebe JU. Antimotility agents for chronic diarrhoea in people with HIV/AIDS. Cochrane Database Syst Rev. 2008;(4):CD005644
Copyright © 2021 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.